IP Verse

Pegylated L-Asparaginase

Patent No. EP2451486 (titled "Pegylated L-Asparaginase") was filed by Alize Pharma II on Jul 6, 2010. The application was issued on Jan 18, 2023.

Patent Summary

PEGylated Erwinia L-asparaginase for treating diseases like cancer that are treatable by L-asparagine depletion. The L-asparaginase is from Erwinia chrysanthemi and conjugated to PEG with a molecular weight less than 5000 Da. The PEGylation improves pharmacological properties compared to unmodified L-asparaginase or pegaspargase. It depletes plasma L-asparagine to undetectable levels for longer durations and has higher potency. The PEGylated Erwinia L-asparaginase is useful as a therapeutic for treating diseases treatable by L-asparagine depletion, such as cancer, in patients who have had relapses after prior L-asparaginase or pegaspargase treatment.

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
MATHYS & SQUIREFeb 2, 2018TITMUS

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP2451486

ALIZE PHARMA II
Application Number
EP10730170A
Filing Date
Jul 6, 2010
Status
Patent Maintained As Amended
Dec 16, 2022
Publication Date
Jan 18, 2023
External Links
Slate, Register , Google Patents